share_log

The Strong Earnings Posted By Hospital Corporation of China (HKG:3869) Are A Good Indication Of The Strength Of The Business

The Strong Earnings Posted By Hospital Corporation of China (HKG:3869) Are A Good Indication Of The Strength Of The Business

中國醫院集團公司(HKG: 3869)公佈的強勁收益很好地表明瞭該業務的實力
Simply Wall St ·  04/29 18:41

Hospital Corporation of China Limited (HKG:3869) just reported healthy earnings but the stock price didn't move much. Our analysis suggests that investors might be missing some promising details.

中國醫院股份有限公司(HKG: 3869)剛剛公佈了可觀的收益,但股價並沒有太大波動。我們的分析表明,投資者可能遺漏了一些令人鼓舞的細節。

earnings-and-revenue-history
SEHK:3869 Earnings and Revenue History April 29th 2024
SEHK: 3869 2024 年 4 月 29 日的收益和收入記錄

How Do Unusual Items Influence Profit?

不尋常的物品如何影響利潤?

Importantly, our data indicates that Hospital Corporation of China's profit was reduced by CN¥136m, due to unusual items, over the last year. It's never great to see unusual items costing the company profits, but on the upside, things might improve sooner rather than later. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And that's hardly a surprise given these line items are considered unusual. If Hospital Corporation of China doesn't see those unusual expenses repeat, then all else being equal we'd expect its profit to increase over the coming year.

重要的是,我們的數據表明,由於異常項目,中國醫院集團公司的利潤在去年減少了1.36億元人民幣。看到不尋常的項目使公司利潤損失從來都不是一件好事,但從好的方面來看,情況可能遲早會好轉。當我們分析全球絕大多數上市公司時,我們發現重大不尋常的事項往往不會重演。鑑於這些單列項目被認爲不尋常,這並不奇怪。如果中國醫院集團不看到這些不尋常的支出重演,那麼在其他條件相同的情況下,我們預計其利潤將在來年增加。

Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Hospital Corporation of China.

注意:我們始終建議投資者檢查資產負債表的實力。點擊此處查看我們對中國醫院集團的資產負債表分析。

Our Take On Hospital Corporation of China's Profit Performance

我們對中國醫院集團盈利表現的看法

Because unusual items detracted from Hospital Corporation of China's earnings over the last year, you could argue that we can expect an improved result in the current quarter. Because of this, we think Hospital Corporation of China's earnings potential is at least as good as it seems, and maybe even better! And it's also positive that the company showed enough improvement to book a profit this year, after losing money last year. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. So while earnings quality is important, it's equally important to consider the risks facing Hospital Corporation of China at this point in time. Every company has risks, and we've spotted 2 warning signs for Hospital Corporation of China (of which 1 is a bit unpleasant!) you should know about.

由於不尋常的項目削弱了中國醫院集團去年的收益,你可能會爭辯說,我們可以預期本季度的業績會有所改善。正因爲如此,我們認爲中國醫院集團的盈利潛力至少和看上去一樣好,甚至可能更好!在去年虧損之後,該公司表現出了足夠的改善,今年實現了盈利,這也是一個積極的因素。本文的目標是評估我們在多大程度上可以依靠法定收益來反映公司的潛力,但還有很多需要考慮的地方。因此,儘管收益質量很重要,但考慮中國醫院集團目前面臨的風險同樣重要。每家公司都有風險,我們發現了中國醫院集團的兩個警告信號(其中一個有點不愉快!)你應該知道。

This note has only looked at a single factor that sheds light on the nature of Hospital Corporation of China's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying to be useful.

這份報告只研究了揭示中國醫院集團利潤性質的單一因素。但是,如果你能夠將注意力集中在細節上,總會有更多的事情需要發現。有些人認爲高股本回報率是優質業務的好兆頭。雖然可能需要你進行一些研究,但你可能會發現這份免費收集的擁有高股本回報率的公司,或者這份內部人士正在購買的股票清單很有用。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論